Prior authorization, not the evidence, is what delays 14 of 18 US oncologists from prescribing a new first-line cancer regimen
14 of 18 US oncologists in the Brox HCP panel say prior authorization or coverage denials, not the trial data or the guideline listing, are what most often delay their first prescription of a newly approved first-line cancer regimen (n=18, October 2026).
- Who was asked
- US oncologists, 18 clones, US
- When
- October 2026 (fielded 9 October 2026)
- How
- Predicted responses from Brox clones, each built from a long-form interview with a real person.
- What changed from the obvious question
- Instead of asking whether oncologists adopt new therapies quickly, it asked separately how soon they first prescribe, what triggers it, what delays it and what they would do before a guideline listing, so the decision and the paperwork can be told apart.
Section 01: What the panel said
- #
14
14 of 18 US oncologists say prior authorization or coverage denials most often delay their first prescription of a newly approved first-line regimen; none named unfamiliar side effects or a formulary review.
base 18
- #
7
Shown a new regimen with a clear survival benefit that is not yet in the NCCN guidelines, 7 of 18 would prescribe it now and 10 would wait, 5 for the listing and 5 for confirmed payer coverage.
base 18 · contrast
- #
10
Asked what a manufacturer could show them to shorten the wait, 10 of 18 chose mature overall survival data and 7 chose confirmed coverage with a patient access program; none chose real-world community data or a side-effect guide.
base 18 · contrast
- #
11
The base is small and mixed: 14 medical, 2 radiation and 2 surgical oncologists. The headline holds among the medical oncologists alone, 11 of 14.
base 14 · Medical oncologists · caveat
14 of 18 US oncologists say prior authorization or coverage denials most often delay their first prescription of a newly approved first-line regimen; none named unfamiliar side effects or a formulary review.
02Is it the evidence or the paperwork that slows a new first-line regimen?
The paperwork. Asked what most often delays their first prescription of a newly approved first-line regimen, 14 of 18 US oncologists named prior authorization or coverage denials. Three named waiting for the guideline listing, one named the patient's out-of-pocket cost, and none named unfamiliar side effects or an institutional pathway or formulary review.
The clinical decision itself is quick. 11 of 18 say they usually first prescribe a newly approved first-line regimen within three months of approval, 3 of them within a month. Our reading is that the oncologist decides early and the payer sets the pace; the panel was asked what delays them most often, not how long each delay lasts.
03Do oncologists wait for the NCCN guidelines before prescribing?
Just over half do. Shown a newly approved regimen with a clear overall survival benefit that is not yet in the NCCN guidelines, 7 of 18 would prescribe it now and 1 only for selected patients, while 10 would wait: 5 for the NCCN listing and 5 for confirmed payer coverage. Among the 14 medical oncologists the lean is earlier, with 6 prescribing now and only 2 waiting for the listing.
Asked what most often triggers a first prescription, 9 of 18 said the NCCN listing and 6 said the pivotal trial data alone. Nobody chose payer coverage as the trigger, even though most named the payer as the delay.
04What would shorten the wait?
Evidence and access, about equally. Asked what a manufacturer could show them that would most shorten the time to a first prescription, 10 of 18 chose mature overall survival data and 7 of 18 chose confirmed payer coverage with a patient access program; among the medical oncologists it was 7 and 7. None chose real-world outcomes from community practice or a side-effect management guide with nurse support.
- Our reading for a launch team: the first months after approval are an access problem as much as an evidence problem, so coverage work started before launch may move first prescriptions more than extra education does.
- Our second reading: survival data still opens the door, so the two need to arrive together rather than one after the other.
05Why only 18 oncologists, and how far does that go?
The Brox HCP panel in the US holds 20 clones in its oncology segment. Reading their interviews, 18 are oncologists (14 medical, 2 radiation, 2 surgical) and 2 are not (a neurologist and an oncology nurse practitioner), so the base for every figure here is 18 and every figure is a count, not a percentage.
That is a small base. It is enough to see a strong pattern, such as 14 of 18 naming the payer, but not to rank close options or to cut by practice setting. The headline holds among the 14 medical oncologists on their own (11 of 14), and the same question asked of the same clones a week earlier gave the same answer.
Section 06: What they said, and the interview line it rests on
“I would definitely have to say prior authorization or coverage denials. When a new regimen comes out, I'm generally eager to use newer therapies and combinations, and I'm very comfortable managing side effects and adverse events, so that doesn't hold me back. We also have our own in-house pharmacy and great institutional capabilities. But the administrative side with insurance is always the real hurdle. Getting unexpected denials and having to navigate the prior authorization and appeals process takes time, and you have to pick and choose your battles before you can actually get the drug into the patient's hands.”
Predicted from this line in the interview
“unexpected denial. I do, on a case-by-case basis, once that happens, we'll kind of pick and choose my battles as far as, going through the appeals process or prior authorization process.”
“For a suitable patient, I would prescribe it now. In my specialty, new therapies that demonstrate a clear overall survival benefit are rare, so when a drug earns approval based on strong clinical trial data, we are eager to evaluate it and start utilizing it as quickly as possible. I wouldn't sit back and wait for the NCCN guidelines to update or wait for payer coverage to become seamless before acting. While navigating reimbursement for newly approved therapies can be challenging, I have a great clinical support team, and I am very willing to write letters of medical necessity, get on the phone with insurance companies, and do whatever is necessary to get my patient the drug they need.”
Predicted from this line in the interview
“I will write letters, I will call the insurance companies, I will fight with whoever I need to to try to get my patient the drug that I think they need.”
“I would wait for the NCCN listing before prescribing it. In my practice, I rely very heavily on the NCCN guidelines to guide treatment choices. When something is officially included as a recommendation in the guidelines, insurance companies really can't deny it, so you avoid all those coverage battles for the patient. Even if the data looks promising, I want to see it vetted and listed in the guidelines first.”
Predicted from this line in the interview
“if it's in the NCCN guidelines, I don't usually have problems with the insurance company, because they really can't deny a treatment that is a Category 1 recommended treatment in the NCCN guidelines.”
Section 07: How much should you trust this?
What we would defend
- Prior authorization and coverage denials are the delay oncologists name first: 14 of 18, 11 of 14 among medical oncologists, and the same question on the same clones a week earlier gave 16 of 20.
- Nobody in the panel chose real-world community data or a side-effect guide as what would most shorten their wait (0 of 18 each).
- The panel splits on prescribing before an NCCN listing: 7 of 18 would prescribe now, 10 would wait.
What we would not
- Any percentage: the base is 18, so every figure is a count.
- That mature survival data beats coverage support as the accelerator: 10 against 7 of 18, and 7 against 7 among the 14 medical oncologists.
- The even 5 and 5 split between waiting for the listing and waiting for the payer.
- Anything about practice setting or experience: the panel holds too few oncologists to cut further.
The main limitation
A small base: the panel's oncology segment holds 20 clones, of whom 18 are oncologists (two, a neurologist and an oncology nurse practitioner, are excluded), and 4 of the 18 are radiation or surgical oncologists who do not usually write first-line systemic prescriptions themselves. Each question was a single forced choice of what happens most often.
Section 08: How was this run?
| Segment | Clones |
|---|---|
| Medical oncology | 14 |
| Radiation oncology | 2 |
| Surgical oncology | 2 |
Question wording as fielded
- Which best describes your clinical specialty?
- When the FDA approves a new first-line regimen in a cancer you treat, how soon after approval do you usually first prescribe it to a suitable patient?
- Which single thing most often triggers your first prescription of a newly approved first-line regimen?
- A newly approved first-line regimen shows a clear overall survival benefit but is not yet listed in the NCCN guidelines. What would you do for a suitable patient today?
- What most often delays your first prescription of a newly approved first-line regimen?
- Which of these could a manufacturer show you that would most shorten the time before you first prescribe a new first-line regimen?
What was not asked, and why
No drug, manufacturer, cancer type or price was named. The study did not ask how long each delay lasts, only which one happens most often, and it did not ask about practice setting.
What changed from the obvious question
Instead of asking whether oncologists adopt new therapies quickly, it asked separately how soon they first prescribe, what triggers it, what delays it and what they would do before a guideline listing, so the decision and the paperwork can be told apart.
Fielded through Ask Brox on 9 October 2026.
More on How doctors decide what to prescribe · Pharma & HCP · HCP (US) panel
Ask this of your own customers: humans@brox.ai
Related insights
All in this topic-
Medical science liaisons: 60.1% of US physicians and other prescribers want real-world and subgroup evidence for patients like theirs, and 65.2% rate a liaison meeting useful against 17.7% for a sales rep
65.2% 65.2% rate a 20-minute meeting with a medical science liaison at least moderately useful to their practice, against 17.7% for a 20-minute meeting with a sales representative about the same kind of medicine (base 198)
Read -
Patient out-of-pocket cost and prescribing: US physicians keep a preferred brand at $25 a month, split at $75, and 62.9% switch to a generic at $150
37.1% 37.1% (26 of 70) would still prescribe the brand-name medicine they prefer when it costs the patient $150 a month against $5 for an older generic, down from 95.7% (67 of 70) at $25 and 55.7% (39 of 70) at $75; none of the 70 moves back to the brand as the price rises. (base 70)
Read -
New medicine launches: 72.9% of US physicians and other prescribers would try one in its first months when it is covered, 22.9% when patients pay $250 a month
22.9% 22.9% (16 of 70) are likely, a 6 or 7 of 7, to prescribe a new medicine with a clear phase 3 benefit in the next three months when most plans do not cover it and a patient pays about $250 a month, against 72.9% (51 of 70) when it is covered with no prior authorization and a $30 copay, and 54.3% (38 of 70) when prior authorization takes one to two weeks. (base 70)
Read -
Pharma rep visits: 66.7% of US clinicians, mostly dermatologists, would turn away a rep who asks to come every two weeks, against 39.4% for a monthly visit
66.7% Asked by a rep for a medicine they already prescribe for a 10-minute in-person visit, 66.2% of US clinicians would agree to one every three months, 58.1% to one a month and 31.8% to one every two weeks; the share who would decline rises from 30.8% to 39.4% to 66.7%. (base 198)
Read